Canopy Growth (TSX:WEED) Stock Gains 7.4% As Earnings Beat Estimates

Canopy Growth (TSX:WEED) managed to outperform analyst earnings estimates in Q1. However, there are far too many uncertainties plaguing the sector right now, making the stock a risky bet.

| More on:

Shares of cannabis giant Canopy Growth (TSX:WEED)(NYSE:CGC) gained over 7.4% on Monday to close trading at $23.93. Canopy Growth announced its first quarter of fiscal 2021 results and reported revenue of $110.4 million, a growth of 22% year-over-year, and a sequential growth of 2%.

Canopy’s net loss stood at $0.30 per share or $128 million, significantly lower than the $1.3 billion loss in the previous quarter. Analysts expected Canopy to post revenue of $112 million and a net loss of $0.35 per share.

We can see while Canopy narrowly missed analyst top-line estimates, it reported a better than expected earnings driving the stock higher. The company’s Q1 sales were driven by a 54% growth in medical marijuana products that now account for 31% of total revenue. Comparatively, recreational cannabis sales fell 11% to $44 million.

Canopy’s lower than expected loss can be attributed to an 18% reduction in the workforce since the start of this year and targeted marketing and R&D expenses.

Cannabis 2.0 extremely critical for Canopy Growth

Canopy Growth, like most other pot stocks, is trying to gain traction in the Cannabis 2.0 segment. The company recently launched its e-commerce site shopcanopy.com in the U.S. while its First & Free brand has expanded into creams, topicals, and ready-to-drink beverages.

The marijuana giant is expanding its product portfolio and already has four cannabis-infused beverages in the market. Canopy has achieved the top position in the beverage segment in terms of dollar share and claims to account for 74% of ready-to-drink cannabis beverages sold year-to-date in Canada.

It has shipped 1.2 million units of its beverages since the end of March compared to 4.2 million units sold across brands in the U.S. last year. Canopy Growth is backed by Constellation Brands, which will help it maintain a leadership position in the beverage space.

During the earnings call CEO David Klein confirmed, “Our Cannabis 2.0 portfolio continues to gain momentum, and we’re adapting quickly to the changes in the marketplace and competitive dynamics.”

Canopy’s focus on cost management

While Canopy Growth continues to grow the top-line, its mounting losses remain a concern for investors. The company is focusing on creating a diversified revenue base as well as cost reduction.

In Q1, its operating expenses fell by 23% year-over-year while capital expenditure was “moderate” compared to the prior-year period. Canopy’s cash outflow improved 50% to $181 million and it ended Q1 with $2 billion in cash.

Canopy is confident that its current infrastructure can support a $2.5 billion business without additional spending in capital expenditure. The company’s CFO Mike Lee said, “We’ve already proven that we can deliver 40% plus gross margins and are confident that we will return to that level as we work toward higher capacity utilization across our facilities.”

He added, “Taking beverages as an example, with the robust demand we’re seeing for our beverages, we are ramping up production and the throughput of our beverage facility has doubled in July from June, and we plan to double again in August.”

The Foolish takeaway

Canopy Growth stock is trading 70% below its record highs. While it has managed to reduce losses in Q1, the company is still a work-in-progress and will need to tide over structural issues that continue to impact the Canadian marijuana sector.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

The Motley Fool owns shares of and recommends Constellation Brands. Fool contributor Aditya Raghunath has no position in any of the stocks mentioned.

More on Cannabis Stocks

Farmer smiles near cannabis crop
Cannabis Stocks

Can Pot Stocks Aurora Cannabis and Canopy Growth Bounce Back in Q4?

Down over 99% from all-time highs, Canadian pot stocks such as Aurora Cannabis and Canopy Growth remain high-risk bets.

Read more »

Worker tags plants at an industrial cannabis operation
Cannabis Stocks

Can Canopy Growth Stock Finally Recover in 2024?

Down 98% from all-time highs, Canopy Growth remains a high-risk investment in 2024 given its weak fundamentals.

Read more »

Tech Stocks

3 No-Brainer Stocks to Buy With $20 Right Now

These three stocks are easy buys for those who don't have all that much to spend, and want long-term growth…

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Slow Burn: Is Aurora Cannabis Finally a Good Buy in June?

One of the benefits of choosing from some of the most beaten-down market segments like cannabis is that even a…

Read more »

Caution, careful
Cannabis Stocks

I Wouldn’t Touch This TSX Stock With a 60-Foot Pole

I wouldn't touch Canopy Growth Corp (TSX:WEED) stock with a 60-foot pole.

Read more »

Cannabis Stocks

Why This Little-Known Cannabis Stock Could Double in 2024

This cannabis stock has already doubled this year since 52-week lows and could easily rise that much once more.

Read more »

Cannabis Stocks

1 TSX Stock I Wouldn’t Touch With a 420-Foot Pole

Down 87% from all-time highs, Cronos Group stock is a still a high-risk investment for long-term shareholders in 2024.

Read more »

A cannabis plant grows.
Cannabis Stocks

Canopy Growth: Buy, Sell, or Hold?

Canopy Growth (TSX:WEED) stock should make a killing on U.S. expansion, but investors will need to be very patient.

Read more »